Terazosin HCl

Catalog No.S4679 Batch:S467901

Print

Technical Data

Formula

C19H25N5O4.HCl
Molecular Weight 423.89 CAS No. 63074-08-8
Solubility (25°C)* In vitro DMSO 84 mg/mL (198.16 mM)
Water 1 mg/mL (2.35 mM)
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Terazosin (Hytrin, Zayasel, Terazosine, Flumarc, Fosfomic, Blavin) is a selective alpha-1 antagonist used for treatment of symptoms of an enlarged prostate (BPH). It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.
Targets
alpha1-AR [1]
In vitro Terazosin induces cytotoxicity in PC-3 and human benign prostatic cells with an IC50 of more than 100 μM. Terazosin also effectively inhibited vascular endothelial growth factor induced proliferation and tube formation in cultured human umbilical vein endothelial cells (IC50 9.9 and 6.8 μM, respectively)[3].
In vivo Terazosin produces a dose-dependent, complete inhibition of motor activity and catalepsy. Intraventricularly administered this antagonist protects striatal and cerebral cortical alpha 1 receptors but not striatal or cortical D1 receptors from in vivo alkylation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroxyquinoline. Intraventricular terazosin also produces hypothermia and a reduced respiratory rate suggestive of a reduced sympathetic outflow. Terazosin does not impair performance on a horizontal wire test or the ability to make co-ordinated movements in a swim test[2].Terazosin significantly inhibits vascular endothelial growth factor induced angiogenesis in nude mice with an IC50 of 7.9 μM, showing that it has a more potent anti-angiogenic than cytotoxic effect[3].

Protocol (from reference)

Cell Assay:

[3]
  • Cell lines

    Human prostate adenocarcinoma PC-3 cells

  • Concentrations

    100 μM

  • Incubation Time

    12 h

  • Method

    To determine the cytotoxic effect mode of action, several identification techniques were used in the current study. Apoptotic cells are detected in situ using terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling. Results show a positive reaction after a 12-hour treatment of PC-3 cells with terazosin (100 μM).
Animal Study:

[1]
  • Animal Models

    Mice

  • Dosages

    0.05 mg/kg

  • Administration

    oral administration

Selleck's Terazosin HCl has been cited by 1 publication

L-Carnitine ameliorates congenital myopathy in a tropomyosin 3 de novo mutation transgenic zebrafish [ J Biomed Sci, 2021, 28(1):8] PubMed: 33435938

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.